UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Phase 2

Terminated

Conditions: Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Nausea and Vomiting
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Larynx

Interventions: Drug: fosaprepitant dimeglumine
Drug: cisplatin
Drug: palonosetron hydrochloride
Drug: dexamethasone
Other: Functional Living Index-Emesis Questionnaire
Behavioral: Emesis Diary
Radiation: Radiotherapy

First Posted Date: 2009-05-08

Last Posted Date: 2017-05-18

Lead Sponsor: University of Washington

Target Recruit Count: 6

Registration Number: NCT00895245

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Outcomes Associated With Application of a Normothermia Protocol in Patients With Severe Neurological Insult and Fever

Not Applicable

Completed

Conditions: Severe Traumatic Brain Injury
Subarachnoid Hemorrhage

Interventions: Other: Stepwise normothermia protocol
Drug: Ibuprofen
Drug: Acetominophen

First Posted Date: 2009-04-30

Last Posted Date: 2024-01-30

Lead Sponsor: University of Washington

Target Recruit Count: 10

Registration Number: NCT00890604

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

Completed

Conditions: Cardiovascular Diseases
Heart Diseases
Atherosclerosis
Coronary Disease
Myocardial Infarction

Interventions: Drug: Simvastatin and Extended-Release niacin
Drug: Simvastatin

First Posted Date: 2009-04-13

Last Posted Date: 2018-05-14

Lead Sponsor: University of Washington

Target Recruit Count: 324

Registration Number: NCT00880178

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Wake Forest University, Endocrinology, Winston-Salem, North Carolina, United States
🇺🇸
McGuire VA Medical Center, Richmond, Virginia, United States

and more 26 locations

Life Improvement Following Traumatic Brain Injury

Not Applicable

Completed

Conditions: Depression
Traumatic Brain Injury

Interventions: Behavioral: Telephone Cognitive Behavioral Therapy
Behavioral: In-person Cognitive Behavioral Therapy

First Posted Date: 2009-04-08

Last Posted Date: 2013-10-18

Lead Sponsor: University of Washington

Target Recruit Count: 100

Registration Number: NCT00878150

Locations: 🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States

Brief Intervention in Primary Care for Problem Drug Use and Abuse

Not Applicable

Completed

Conditions: Substance-Related Disorders

Interventions: Behavioral: Brief intervention using motivational interviewing

First Posted Date: 2009-04-07

Last Posted Date: 2014-10-20

Lead Sponsor: University of Washington

Target Recruit Count: 868

Registration Number: NCT00877331

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Pregnancy-Induced Analgesia - A Longitudinal Study of DNIC

Conditions: Pregnancy

First Posted Date: 2009-03-24

Last Posted Date: 2013-06-19

Lead Sponsor: University of Washington

Target Recruit Count: 60

Registration Number: NCT00867945

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
University of Washington, Seattle, Washington, United States

Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)